×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
COMBINATION MEDICINAL DRUG PRODUCTS OF KNOWN ACTIVE SUBSTANCES
Session Chair(s)
Christer Backman, LLM
International Coordinator & Senior Expert
Medical Products Agency, Sweden
Form the patient’s perspective combination medicinal products bear potential benefits. For industry such products may be promising as they provide innovations with only incremental research efforts. National agencies’ attitudes towards combination medicinal products, however, are still diverse and lack a harmonised approach.
Speaker(s)
Agency’s View on Combination Medicinal Products – A disputed topic
Christer Backman, LLM
Medical Products Agency, Sweden
International Coordinator & Senior Expert
Known Active Substances in Fixed Dose Combination Products: An area of investigations for industry?
Alexander Natz, JD
European Confederation of Pharmaceutical Entrepreneurs, Belgium
Secretary General
Expectations and Benefits of Combination Medicinal Products from the Patient’s Perspective
Maren von Fritschen, PharmD
Moderna, Netherlands
Head EU Regulatory Policy
Have an account?